These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 20567945)

  • 21. Guidelines for the therapeutic use of botulinum toxin in movement disorders.
    Pagni CA
    Ital J Neurol Sci; 1998 Jun; 19(3):189-90. PubMed ID: 10933476
    [No Abstract]   [Full Text] [Related]  

  • 22. Botulinum Toxin in Movement Disorders: An Update.
    Anandan C; Jankovic J
    Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33430071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum toxin in movement disorders.
    Tater P; Pandey S
    Neurol India; 2018; 66(Supplement):S79-S89. PubMed ID: 29503330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin: historical perspective and potential new indications.
    Jankovic J; Brin MF
    Muscle Nerve Suppl; 1997; 6():S129-45. PubMed ID: 9826986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Botulinum toxin therapy: from dreaded biological toxin to standard pharmaceutical].
    Schnider P; Voller B; Moraru K; Auff E
    Wien Klin Wochenschr; 1999 Oct; 111(20):825-9. PubMed ID: 10586486
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of intractable tardive lingual dyskinesia with botulinum toxin.
    Beckmann YY; Seçil Y; Saka S; Kuserli A; Çiftçi Y
    J Clin Psychopharmacol; 2011 Apr; 31(2):250-1. PubMed ID: 21364341
    [No Abstract]   [Full Text] [Related]  

  • 27. Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations.
    Frei K; Truong DD; Dressler D
    Eur J Neurol; 2006 Feb; 13 Suppl 1():30-5. PubMed ID: 16417595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Botulinum toxin in the management of bowel and bladder function in spinal cord injury and other neurologic disorders.
    Dykstra DD
    Phys Med Rehabil Clin N Am; 2003 Nov; 14(4):793-804, vi. PubMed ID: 14580038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Laryngeal electromyography in movement disorders: preliminary data.
    Kimaid PA; Quagliato EM; Crespo AN; Wolf A; Viana MA; Resende LA
    Arq Neuropsiquiatr; 2004 Sep; 62(3A):741-4. PubMed ID: 15334243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The use of botulinum toxin in otorhinolaryngology--experiences and outlook].
    Laskawi R
    Laryngorhinootologie; 1997 Nov; 76(11):656-9. PubMed ID: 9517972
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacotherapy with botulinum toxin: harnessing nature's most potent neurotoxin.
    Bell MS; Vermeulen LC; Sperling KB
    Pharmacotherapy; 2000 Sep; 20(9):1079-91. PubMed ID: 10999501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurobiological basis for the use of botulinum toxin in pain therapy.
    Mense S
    J Neurol; 2004 Feb; 251 Suppl 1():I1-7. PubMed ID: 14991335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum toxin in motor disorders: practical considerations with emphasis on interventional neurophysiology.
    Traba López A; Esteban A
    Neurophysiol Clin; 2001 Aug; 31(4):220-9. PubMed ID: 11596529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Botulinum toxins for pain].
    Soinila S; Haanpää M
    Duodecim; 2011; 127(22):2425-30. PubMed ID: 22238920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin in rare pain syndromes.
    Naumann M; Eberhardt B; Laskawi R; Porta M; Schnider P; Sostak P; Lutze M
    J Neurol; 2004 Feb; 251 Suppl 1():I39-40. PubMed ID: 14991343
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical value of botulinum toxin in neurological indications.
    Ward AB; Molenaers G; Colosimo C; Berardelli A
    Eur J Neurol; 2006 Dec; 13 Suppl 4():20-6. PubMed ID: 17112346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanding use of botulinum toxin.
    Bhidayasiri R; Truong DD
    J Neurol Sci; 2005 Aug; 235(1-2):1-9. PubMed ID: 15990116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemodenervation with botulinum toxin for spasticity and dystonia. The effects on gait.
    O'Brien CF
    Adv Neurol; 2001; 87():265-9. PubMed ID: 11347231
    [No Abstract]   [Full Text] [Related]  

  • 39. Botulinum toxin--mechanisms of action and clinical use in spasticity.
    Barnes M
    J Rehabil Med; 2003 May; (41 Suppl):56-9. PubMed ID: 12817658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction.
    Lew MF
    Clin J Pain; 2002; 18(6 Suppl):S142-6. PubMed ID: 12569961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.